These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 30730552)
1. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552 [TBL] [Abstract][Full Text] [Related]
2. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585 [TBL] [Abstract][Full Text] [Related]
3. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341 [TBL] [Abstract][Full Text] [Related]
4. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204 [TBL] [Abstract][Full Text] [Related]
6. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085 [TBL] [Abstract][Full Text] [Related]
7. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391 [TBL] [Abstract][Full Text] [Related]
9. Germline pathogenic variants in unselected Korean men with prostate cancer. So MK; Ahn HK; Huh J; Kim KH Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218 [TBL] [Abstract][Full Text] [Related]
11. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
12. Bringing Prostate Cancer Germline Genetics into Clinical Practice. Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047 [TBL] [Abstract][Full Text] [Related]
14. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA; Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936 [TBL] [Abstract][Full Text] [Related]
16. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945 [TBL] [Abstract][Full Text] [Related]
17. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238 [TBL] [Abstract][Full Text] [Related]